Speciality Medicines
CLOSEDIPO Date: 20 Mar - 24 Mar 2026
Listing Date: 30 Mar 2026
Price Range
Rs.117 - Rs.124
Issue Size
29 Cr
Min Investment
₹1,17,000
Lot Size
1000 Shares
Schedule of Speciality Medicines
Issue open date
20 Mar 2026
Issue close date
24 Mar 2026
UPI mandate deadline
24 Mar 2026 (5 PM)
Allotment finalization
25 Mar 2026
Share credit
27 Mar 2026
Listing date
30 Mar 2026
Mandate end date
9 Apr 2026
Issue size
| Funds Raised in the IPO | Amount |
|---|---|
| Overall | 29 Cr |
| Fresh Issue | 29.14 Cr |
| Offer for Sale | 0 Cr |
Allotment DetailsNew
| Allotment Timeline | Details |
|---|---|
| Allotment Date | 25 Mar 2026 |
| Allotment Link | {Link} |
Grey Market PremiumNew
Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.
| Date | Ipo Price | GMP | Estimated Listing Price |
|---|---|---|---|
| 29 Mar 2026 | ₹124 | ₹0 | ₹124 (0%) |
| 28 Mar 2026 | ₹124 | ₹0 | ₹124 (0%) |
| 27 Mar 2026 | ₹124 | ₹0 | ₹124 (0%) |
| 26 Mar 2026 | ₹124 | ₹0 | ₹124 (0%) |
| 23 Mar 2026 | ₹124 | ₹0 | ₹124 (0%) |
| 22 Mar 2026 | ₹124 | ₹0 | ₹124 (0%) |
| 21 Mar 2026 | ₹124 | ₹0 | ₹124 (0%) |
| 19 Mar 2026 | ₹124 | ₹0 | ₹124 (0%) |
| 18 Mar 2026 | ₹124 | ₹0 | ₹124 (0%) |
| 17 Mar 2026 | ₹124 | ₹0 | ₹124 (0%) |
Performance Speciality Medicines
| Issue Price | Listing Gain | Current Market Price | P/L |
|---|---|---|---|
| Rs.117 - Rs.124 | ₹ 280 (0%) | ₹ 163.05 | 31.49% |
About Speciality Medicines
Speciality Medicines Limited is engaged in the marketing and distribution of finished formulations of speciality pharmaceutical products used in the treatment of complex and chronic medical conditions. These products are primarily used in therapeutic areas such as oncology, immunology, neurology, and rare diseases. The company offers a portfolio of speciality medicines available in multiple dosage forms, including tablets, capsules, syrups, injections, infusions, inhalers, creams, gels, ointments, eye drops, nasal sprays, oral solutions, and suspensions. Its operations follow two integrated models: contract manufacturing of approved finished formulations through third-party manufacturers in India for international distribution and marketing and distribution of speciality pharmaceutical products sourced from manufacturers. Under the distribution model, the company handles procurement, warehousing, and wholesale supply of medicines to healthcare providers and retailers. As of March 31, 2025, the company’s portfolio included more than 900 products, and its distribution network covered more than 20 states in India and over 35 countries globally.
| Founded in | 2021 |
| Managing director | Mr Parth Goyani |
| Parent organization |
Financial Overview
Strengths
- Focuses on speciality medicines for complex and chronic diseases.
- Diverse product portfolio across multiple therapeutic areas.
- A wide range of dosage forms enhances product reach.
- Dual business model of manufacturing and distribution.
- Presence in international markets through a distribution network.
Risks
- Dependence on third-party manufacturers for product supply.
- High reliance on a few key customers for revenue.
- Strict quality requirements may lead to order cancellations.
- Ongoing legal proceedings involving a promoter.
- Exposure to supply disruptions and price volatility.
Subscription Figures
| Category | Subscription (No. of times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 96.24 |
| Non-Institutional Investors (NIIs) | 1.75 |
| Retail Individual Investors (RIIs) | 0.78 |
| Employee | N/A |
| Total | 2.14 |